AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Small ribosomal subunit protein uS3m

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96EL2

UPID:

RT24_HUMAN

Alternative names:

28S ribosomal protein S24, mitochondrial; bMRP-47

Alternative UPACC:

Q96EL2; A4D1U9; P82668; Q96Q23; Q9P047

Background:

The Small ribosomal subunit protein uS3m, also known as 28S ribosomal protein S24, mitochondrial and bMRP-47, plays a crucial role in the mitochondrial ribosome. Its primary function involves the translation of mitochondrial DNA-encoded proteins, essential for mitochondrial biogenesis and function. This protein's unique structure and localization underscore its importance in cellular energy production and metabolic processes.

Therapeutic significance:

Understanding the role of Small ribosomal subunit protein uS3m could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial protein synthesis makes it a key target for interventions aimed at mitochondrial diseases and disorders related to energy metabolism.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.